CVS HEALTH financials
$87.10−0.85%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $399.83B | $370.66B | $356.62B | $321.63B | $290.91B | $267.91B | $255.76B | $193.92B | $184.76B | $177.53B |
| Gross profit | $53.13B | $49.25B | $53.28B | $53.66B | $50.92B | $48.25B | $44.52B | $30.88B | $28.51B | $28.81B |
| Gross margin | 13.3% | 13.3% | 14.9% | 16.7% | 17.5% | 18.0% | 17.4% | 15.9% | 15.4% | 16.2% |
| Operating income | $2.43B | $6.36B | $12.59B | $7.12B | $12.11B | $13.11B | $10.98B | $3.36B | $9.52B | $10.37B |
| Net income | $1.77B | $4.61B | $8.34B | $4.31B | $8.00B | $7.18B | $6.63B | -$597.0M | $6.60B | $5.29B |
| Net margin | 0.4% | 1.2% | 2.3% | 1.3% | 2.8% | 2.7% | 2.6% | −0.3% | 3.6% | 3.0% |
| Diluted EPS | $1.39 | $3.66 | $6.47 | $3.26 | $6.02 | $5.46 | $5.08 | $-0.57 | $6.44 | $4.90 |
| EBITDA | $12.76B | $12.14B | $17.81B | $19.68B | $18.39B | $17.55B | $15.58B | $12.23B | $12.18B | $12.84B |
| Operating cash flow | $10.64B | $9.11B | $13.43B | $16.18B | $18.27B | $15.87B | $12.85B | $8.87B | $8.01B | $10.14B |
| Free cash flow | $7.81B | $6.33B | $10.39B | $13.45B | $15.74B | $13.43B | $10.39B | $6.83B | $6.09B | $7.92B |
| Diluted shares | 1,271.0M | 1,262.0M | 1,290.0M | 1,323.0M | 1,329.0M | 1,314.0M | 1,305.0M | 1,044.0M | 1,024.0M | 1,079.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $8.45B | $8.59B | $8.20B | $12.95B | $9.41B | $7.85B |
| Short-term investments | $2.15B | $2.41B | $3.26B | $2.78B | $3.12B | $3.00B |
| Total debt | $64.57B | $66.27B | $61.61B | $52.25B | $56.18B | $64.65B |
| Total assets | $253.54B | $253.22B | $249.73B | $228.28B | $233.00B | $230.72B |
| Total liabilities | $178.16B | $177.49B | $173.09B | $156.51B | $157.62B | $161.01B |
| Shareholders' equity | $75.38B | $75.73B | $76.64B | $71.77B | $75.38B | $69.70B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology